Recombinant Anti-CCR5 x Anti-CD3 Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CCR5 antibody variable domain is fused to the C terminal of an IgG of anti-CD3 antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can retarget T cells to CCR5 target cells. It is designed for the research of HIV-1 infection, AIDS therapy.